Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study.

16 The study using Sweden SWEDEHEART registry showed that ticagrelor reduced all‐cause death at 24 months compared to clopidogrel (aHR 0.83, 95% CI 0.75–0.92), yet marginally insignificant in MI reduction (aHR 0.89, 95% CI 0.78–1.01) and stroke (aHR 0.81, 95% CI 0.65–1.01). 17 Two observational studies in Korea revealed reduced all‐cause mortality and CV death using ticagrelor compared to clopidogrel at 24 months. 9 , 18 Our study examined outcomes beyond 1 year up to 5 years after index ACS event.

also in 511 other papers